Improved Immunoassay Diagnostic Tests


To improve the speed and sensitivity of immunoassays using environmentally sensitive (smart) polymer technology

Anticipated Impact: 

Improved clinical decision-making resulting from faster and more sensitive immunoassays


Immunoassays are critical tools used to guide clinical decision-making. They are involved in diagnosing and monitoring a host of diseases, including cancer, and cardiac and endocrine diseases. The smart polymer technology developed by the research team has the potential to enable both faster and more sensitive assays, and reagents developed with this technology may be readily adapted to current automated immunoassay systems. Under this grant, next-generation immunoassay reagents will be developed and tested in a model hormone assay using human samples. The investigators will directly compare their smart polymer-based immunoassay reagents with immunoassay reagents using current technology. A new company is planned to commercialize the reagents should proof of concept be demonstrated.

Collaborating organization: Nexgenia

See also:

Improved Immunoassay Diagnostic Tests

Grant Update

Principal Investigator:
Patrick Stayton
Grantee Organization:
University of Washington
Grant Title:
Next Generation High Speed Immunoassay
Grant Cohort and Year:
2010 Second Round Commercialization (04)
Grant Period:
07/01/2011 - 06/30/2013 (Completed)
Grant Amount:
This project aims to develop magnetic nanoparticle antibody conjugates as reagents for commercial immunoassay technology. Clinical immunoassays remain one of the primary tools in disease diagnosis and monitoring in all areas of medicine. The nanomaterial-based reagents are designed to significantly improve the sensitivity and throughput of these clinical diagnostic systems. The technology if successful could improve existing tests and provide the needed sensitivity for emerging biomarkers of cancer, heart disease, and other critical medical conditions. After the initial reagent development, the team has moved forward with the evaluation. The preliminary data show the developed reagents can capture more target biomarkers faster then the commercially available main stream magnetic microbead reagents. Therefore, these reagents can potentially enable faster assays.

Impact in Washington

Location of LSDF Grantee
Locations of Collaborations/Areas of Impact

Legislative Districts:
11, 34, 36, 37, 43, 46

Health Impacts

Improved Immunoassay Diagnostic Tests